Research Insight

AstraZeneca’s type 2 diabetes treatment Xigduo XR obtains FDA...

British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with...

Pfizer’s Trumenba gets FDA accelerated approval to treat Meningococcal...

US-based drugmaker Pfizer has received accelerated approval from US Food and Drug Administration (FDA) for its Trumenba to treat Meningococcal B disease in...

Hikma to market Eisai’s epilepsy treatment Fycompa in Middle...

UK-based Hikma Pharmaceuticals has partnered with Eisai to distribute first-class epilepsy treatment Fycompa (perampanel) in the Middle East. Eisai has...

Gilead’s Harvoni receives FDA approval for hepatitis C genotype...

Gilead Sciences has received approval from US Food and Drug Administration for Harvoni (ledipasvir 90mg/sofosbuvir 400mg), a once-daily single tablet regimen to treat...

EMD Serono, ICR and Wellcome Trust partner develop anti-cancer...

Merck subsidiary EMD Serono, The Institute of Cancer Research (ICR) and the Wellcome Trust have entered into a co-development and licence agreement for...

UK’s Medical Research Council grants fund for three new...

The UK Medical Research Council (MRC) has granted a fund of £6m for three new research programmes, as part of a £60m investment. The ...

Novartis and BMS enter clinical collaboration to assess lung...

Swiss drug maker Novartis has partnered with US-based Bristol-Myers Squibb (BMS) to assess the safety, tolerability and preliminary efficacy of its three molecularly...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read